Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine (CARSPECT II)
Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Marion CHANCHOU, Dr
- 전화번호: 33473278089
- 이메일: marion.chachou@clermont.unicancer.fr
연구 장소
-
-
-
Clermont-Ferrand, 프랑스
- Chu Clermont Ferrand
-
연락하다:
- SYLVAIN MATHIEU
- 전화번호: MD
- 이메일: smathieu@chu-clermontferrand.fr
-
-
PUY DE DOME
-
Clermont-Ferrand, PUY DE DOME, 프랑스, 63011
- Centre Jean Perrin
-
연락하다:
- MARION CHANCHOU, MD
- 전화번호: 04 73 27 82 01
- 이메일: Marion.chanchou@clermont.unicancer.fr
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Karnofsky index > 70%
- Obtaining written, signed and dated informed consent
- Affiliation to a health insurance plan
- For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.
- Ability and willingness to respect study visits, exams as well as protocol.
RA Group:
- certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria,
- symptomatic (finger pain > 4 /10 on a numerical scale),
- active synovitis (clinical and ultrasound),
Group DOA:
- certain diagnosis of symptomatic DOA less than 5 years old (finger pain > 4 /10 on a numerical scale),
- stopping NSAIDs for at least 8 days before the injection,
Exclusion Criteria:
- Ongoing use of non-steroidal anti-inflammatory drugs,
- Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,
- History of osteoarticular hand surgery.
- History of hand soft tissue surgery in the past 6 months
- Patients or patients 18 years old,
- Pregnant or breastfeeding patient,
- IMC>30,
- History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,
- Persons deprived of their liberty, under guardianship/curatorship, or safeguarding of justice,
- Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study.
RA Group:
- Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.
- Patients with a history of hand DOA
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Rheumatoid arthritis
99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
|
15 MBq/kg(D0)의 진단 활성에서 99mTc-NTP 15-5 정맥 주사 1회
|
|
실험적: digital osteoarthritis
99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
|
15 MBq/kg(D0)의 진단 활성에서 99mTc-NTP 15-5 정맥 주사 1회
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group: digital osteoarthritis (DOA) and rheumatoid arthritis (RA)
기간: 2 hour after injection
|
The diagnostic accuracy of 99mTc-NTP 15-5 imaging in detecting an abnormal joint among the 15 joints of the hands.
The scintigraphic analysis of the joints will be visual, blinded to the pathology, and binary in nature.
A joint will be considered pathological on 99mTc-NTP 15-5 in the event of abnormal tracer uptake, compared to joints with physiological uptake.
The diagnosis of a pathological joint (gold standard) will be based on a composite radiological-clinical analysis.
|
2 hour after injection
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
to evaluate the diagnostic performance of 99mTc-NTP 15-5 for differential diagnosis between DAO and RA.
기간: 2 hours after injection of 99mTc-NTP 15-5
|
Performance measures of 99mTc-NTP 15-5 imaging for distinguishing between DAO and RA. Readers will classify the scintigrams as DAO or RA based on the uptake pattern. A consensus will be sought in cases of disagreement. The gold standard will be the diagnosis determined by radioclinical analysis. |
2 hours after injection of 99mTc-NTP 15-5
|
|
to evaluate the performance of 99mTc-NTP imaging 15-5 by joint group in each pathology.
기간: 2 hours after injection
|
Performance measures of 99mTc-NTP 15-5 imaging to detect an affected joint complex
|
2 hours after injection
|
|
to determine the prevalence of joint damage by pathology according to the scintigraphic method and the radioclinical method
기간: 2 hours after injection
|
The proportion of joints classified as pathological, according to the scintigraphic method and the radioclinical method
|
2 hours after injection
|
|
To quantitatively analyze the fixation of 99mTc-NTP 15-5 on the hand joints, in each pathology.
기간: 2 hours after injection
|
measurements of the joint/radial diaphysis ration (99mTc-NTP 15-5A/D), determined by semi-automatic contouring joint interfaces on tomoscintigraphic images and manually traced spherical region of interest on radial diaphyses.
|
2 hours after injection
|
|
to evaluate the inter-observer reproducibility of visual and quantitative readings
기간: 2 hours after injection
|
Inter-observer reproducibility measures: Cohen's kappa coefficient for visual readings (before to consensus) and intra-class correlation coefficient (ICC) for quantitative readings.
|
2 hours after injection
|
|
to describe the fixation of 99mTc-NTP 15-5 on skeletal joints other than hand joints, based on visual analysis.
기간: 2 hours after injection
|
All skeletal joints other than the hands will be rated by a score : 0: no fixation, 1: fixation < adjacent diaphysis, 2: fixation = adjacent diaphysis, 3: fixation > adjacent diaphysis.
|
2 hours after injection
|
|
to evaluate the tolerance of 99mTc-NTP 15-5.
기간: during 1 week after injection of 99mTc-NTP 15-5
|
Adverse events (AEs) assessed according to the NCI-CTCAE V5.0 criteria and associated with 99mTc-NTP 15-5 occurring within the week following the injection.
|
during 1 week after injection of 99mTc-NTP 15-5
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Marion CHANCHOU, Dr, Centre Jean Perrin
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- 2025-523650-14-00
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .